ITRM ITERUM THERAPEUTICS PLC Investments/Divestments 8-K Filing 2024 - Business Update Iterum Therapeutics plc announced that it expects to resubmit its new drug application for oral sulopenem to the FDA earlier than planned and believes its existing cash and investments will fund its operating expenses into 2025.Get access to all SEC 8-K filings of the ITERUM THERAPEUTICS PLC